To evaluate the biological outcomes of elevated SDC1 expression in MM patients, we grouped all MM patients into two groups based on SDC1 expression and found that patients featuring lower SDC1 levels had improved overall survival outcomes compared to those with higher SDC1 levels (Figure 6A). The gene discussed is SDC1; the disease is Miyoshi myopathy.